Li Jinlu, Yang Kaihong, Yao Fuchao, Wei Hui
School of Nursing and Rehabilitation, Cheeloo College of Medicine, Shandong University, Jinan, China.
Rehabilitation Center, Qilu Hospital of Shandong University, Jinan, China.
Front Pharmacol. 2024 Sep 18;15:1469223. doi: 10.3389/fphar.2024.1469223. eCollection 2024.
Neuropathic pain (NP) is a kind of chronic pain that has attracted much attention in clinical practice, characterized by high morbidity, complex mechanisms, and difficulties in clinical treatment, with which the activation of High mobility group box 1 (HMGB1) is closely related. The aim of this study was to investigate the effects of lentivirus-mediated RNA interference gene therapy targeting HMGB1 on neuropathic pain in rats with chronic dorsal root ganglion compression (CCD) and its specific mechanisms, so as to explore new pharmacological targets.
Adult male Wistar rats were surgically subjected to chronic compression of the dorsal root ganglia (CCD). Behavioral tests were performed by calculating the paw withdrawal mechanical threshold (PWMT) and the thermal paw withdrawal latency (TPWL). Co-immunoprecipitation (CO-IP) was used to clarify protein interactions. Gene silencing was induced by injecting lentivirus expressing HMGB1 short hairpin RNA (shRNA) into rats. An LPS-inflammation-stimulated rat astrocyte model was established to validate the animal experiment results further. Western blot analysis and real-time quantitative PCR were used to detect pathway protein expression.
After first establishing the rat CCD model, both PWMT and PTWL were significantly reduced in rats, indicating that the model construction was successful. After lentiviral silencing of HMGB1 expression, NP was significantly alleviated in CCD rats. CO-IP experiments showed a link between HMGB1 and AQP1; After silencing HMGB1 expression, the expression of AQP1 was significantly reduced, and HMGB1 was able to modulate the effect of AQP1 on NP. Further use of an inhibitor of the HMGB1 receptor showed that after inhibition of RAGE, AQP1 was significantly reduced; HMGB1 may regulate AQP1 through its receptor RAGE to affect NP. Silencing of HMGB1 resulted in a significant decrease in NF-κB, and HMGB1 affects the inflammatory pathways it mediates. After silencing AQP1, NF-κB also decreased significantly, indicating that AQP1 is an upstream regulator of NF-κB.
Lentivirus-mediated RNA interference (RNAi) silencing targeting HMGB1 may play a key role in the development of neuropathic pain in rats by regulating AQP1 expression via RAGE and ultimately activating NF-κB.
神经病理性疼痛(NP)是一种在临床实践中备受关注的慢性疼痛,其特点是发病率高、机制复杂且临床治疗困难,与高迁移率族蛋白B1(HMGB1)的激活密切相关。本研究旨在探讨慢病毒介导的靶向HMGB1的RNA干扰基因治疗对慢性背根神经节压迫(CCD)大鼠神经病理性疼痛的影响及其具体机制,以探索新的药理学靶点。
成年雄性Wistar大鼠接受背根神经节慢性压迫(CCD)手术。通过计算 paw withdrawal mechanical threshold(PWMT)和热缩爪潜伏期(TPWL)进行行为测试。采用免疫共沉淀(CO-IP)法阐明蛋白质相互作用。通过向大鼠注射表达HMGB1短发夹RNA(shRNA)的慢病毒诱导基因沉默。建立脂多糖炎症刺激的大鼠星形胶质细胞模型以进一步验证动物实验结果。采用蛋白质免疫印迹分析和实时定量PCR检测通路蛋白表达。
首先建立大鼠CCD模型后,大鼠的PWMT和PTWL均显著降低,表明模型构建成功。慢病毒沉默HMGB1表达后,CCD大鼠的NP明显减轻。CO-IP实验显示HMGB1与水通道蛋白1(AQP1)之间存在联系;沉默HMGB1表达后,AQP1的表达显著降低,且HMGB1能够调节AQP1对NP的影响。进一步使用HMGB1受体抑制剂显示,抑制晚期糖基化终末产物受体(RAGE)后,AQP1显著降低;HMGB1可能通过其受体RAGE调节AQP1以影响NP。沉默HMGB1导致核因子κB(NF-κB)显著降低,且HMGB1影响其介导的炎症通路。沉默AQP1后,NF-κB也显著降低,表明AQP1是NF-κB的上游调节因子。
慢病毒介导的靶向HMGB1的RNA干扰(RNAi)沉默可能通过RAGE调节AQP1表达并最终激活NF-κB,在大鼠神经病理性疼痛的发生发展中起关键作用。